Role of biomarkers to predict outcomes and response to therapy

Urologic Oncology
Yair Lotan

Abstract

Molecular markers are not established in management of bladder cancer. There is, however, a limit to the ability of clinical and pathological parameters to predict patients at high risk for urothelial carcinoma of the bladder (UCB) recurrence or mortality. The assessment of molecular biomarkers in surgical UCB specimens offers additional information on the biology of the disease, and might improve the prediction of oncologic end points. There is also a potential for molecular biomarkers to predict the response to adjuvant or neoadjuvant therapies. Furthermore, markers may guide targeted therapy. Prospective trials are needed to validate the clinical benefit of assessing expression patterns of molecular biomarkers.

References

Nov 10, 1994·The New England Journal of Medicine·D EsrigR J Cote
Nov 15, 2002·International Journal of Cancer. Journal International Du Cancer·Stefan KrügerAndreas Böhle
Feb 26, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shahrokh F ShariatSeth P Lerner
Jul 16, 2005·Urologic Oncology·Seth P Lerner
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Silvia HernándezFrancisco X Real
Aug 20, 2005·Nature Reviews. Cancer·Xue-Ru Wu
Sep 1, 2005·The Lancet Oncology·Núria MalatsFrancisco X Real
Jan 25, 2006·Critical Reviews in Oncology/hematology·P TherasseJ Bogaerts
Jul 4, 2006·The Journal of Urology·Wassim KassoufColin P N Dinney
Jul 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN International Bladder Cancer Nomogram ConsortiumKinjal C Vora
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Mar 27, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Shahrokh F ShariatYair Lotan
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maha H A HussainUNKNOWN National Cancer Institute
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne B AlsTorben F Orntoft
Oct 9, 2007·European Urology·Karim BensalahShahrokh F Shariat
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ben GeorgeRichard J Cote
Dec 20, 2007·Current Opinion in Urology·Shahrokh F ShariatSeth P Lerner
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Oct 9, 2008·Journal of the National Cancer Institute·Margaret S PepeJohn D Potter
Dec 4, 2008·Nature Clinical Practice. Urology·Christian Bolenz, Yair Lotan

❮ Previous
Next ❯

Citations

Jul 9, 2010·Urologic Oncology·Shahrokh F ShariatNuria Malats
Oct 22, 2013·The Journal of Urology·Tobias Klatte, Shahrokh F Shariat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.